News

Hanford Pharmaceuticals has completed the sale of its Cephalosporin manufacturing facility in Syracuse, NY, on September 24, 2009. As part of the deal, Hanford will continue to manufacture

Actavis has launched the antiepileptic drug Topiramate in the UK, Germany, France and Switzerland. The product was launched on day one as the originator’s patent expired on 25

Precision BioSciences has announced that the US Patent and Trademark Office (USPTO) has granted Precision’s requests for inter partes reexamination of US Patent Nos 6610545 (the ‘545 patent)

Watson Pharmaceuticals has posted findings of a double-blind study which demonstrate that Gelnique was comparable to placebo in its effect on memory tests and other cognitive functions in

Icagen has initiated a proof-of-mechanism study of ICA-105665 for the treatment of pain. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, to treat certain

Cell Therapeutics (CTI) has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in

Alimera Sciences has reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien. The 36-month, open-label, phase 2 study, running

ImThera Medical, has received Ethics Committee clearance to begin human clinical trials in Belgium. The trials will include ImThera’s Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy to treat obstructive

InterMune has announced that its partner Roche has begun dosing in a phase 1b multiple ascending dose (MAD) study of ITMN-191 (RG7227) boosted by low-dose ritonavir in patients